For the year ending 2025-12-31, DRMAW had $4,360,408 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total research and development | 2,929,983 |
| Total selling, general and administrative | 4,843,615 |
| Interest income | 215,041 |
| Net loss | -7,558,557 |
| Stock-based compensation | 143,732 |
| Prepaid expenses and other current assets | -30,470 |
| Accounts payable | -388,056 |
| Accrued and other current liabilities | 14,852 |
| Net cash used in operating activities | -7,757,559 |
| Proceeds from issuance of common stock, pre-funded warrants, and warrants, net of issuance costs | 12,167,852 |
| Payment of prior period issuance costs | 50,495 |
| Proceeds from exercise of pre-funded warrants | 977 |
| Payment for fractional shares in reverse stock split | -367 |
| Net cash provided by financing activities | 12,117,967 |
| Net increase (decrease) in cash and cash equivalents | 4,360,408 |
| Cash and cash equivalents at beginning of period | 3,161,570 |
| Cash and cash equivalents at end of period | 7,521,978 |
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)